Red Light Holland Receives Official Psilocybin COA Through FDA-Compliant, DEA-Registered Partner, Irvine Labs, USA

Executive Summary

• Red Light Holland received an official Certificate of Analysis from its partner Irvine Labs confirming psilocybin potency and process validation for potential medical‑grade manufacturing.
• The validated material was shipped from the Netherlands to Irvine Labs’ FDA‑compliant, DEA‑registered facility in California, demonstrating compatibility with upcoming manufacturing processes.
• The company is preparing a larger export of psilocybin under Irvine Labs’ 2025 DEA quota, advancing its roadmap toward standardized therapeutic products and clinical‑trial supply.

Key Details

• Certificate of Analysis (COA) confirms psilocybin potency in naturally derived truffles from the Netherlands facility.
• Samples were shipped to Irvine Labs’ FDA‑compliant, DEA‑registered laboratory in California for testing.
• Results verify that the material is compatible with manufacturing processes being developed for potential medical‑grade applications.
• Ongoing work includes proprietary dehydration and packaging methods aimed at extending shelf life while preserving product integrity.
• Red Light Holland plans a larger psilocybin export under Irvine Labs’ existing 2025 DEA quota allocation.
• The validation marks significant progress toward standardized psilocybin products for emerging therapeutic markets, government‑funded pilot programs, and clinical trials.

Notable Quotes

(No direct quotes were provided in the release.)